Patient Guide: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 14 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04903314
Status: 🟢 Enrolling Now
Condition: Partial Epilepsy
Phase: PHASE1

Where You Can Participate

This study is available at 14 locations across the country.

Top locations include:
  • • Phoenix, Arizona
  • • Bethesda, Maryland
  • • Columbia, Missouri
  • • And 11 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures - Join Clinical Trial NCTNCT04903314

How to Join This Clinical Trial - NCTNCT04903314

Learn how to participate in this PHASE1 trial studying an investigational therapy for Partial Epilepsy. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Partial Epilepsy. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Partial Epilepsy
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT04903314 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 14 locations. Find a study site near you:

Clinical Research Site

Phoenix, Arizona 85016 - United States

Status: RECRUITING

Clinical Research Site

Bethesda, Maryland 20817 - United States

Status: RECRUITING

Clinical Research Site

Columbia, Missouri 65201 - United States

Status: TERMINATED

Clinical Research Site

Hackensack, New Jersey 07601 - United States

Status: RECRUITING

Clinical Research Site

Morristown, New Jersey 07960 - United States

Status: WITHDRAWN

Clinical Research Site

Durham, North Carolina 27705 - United States

Status: RECRUITING

Clinical Research Site

Cincinnati, Ohio 45229 - United States

Status: RECRUITING

Clinical Research Site

Memphis, Tennessee 38103 - United States

Status: RECRUITING

Clinical Research Site

Tacoma, Washington 98405 - United States

Status: RECRUITING

Clinical Research Site

Budapest, - Hungary

Status: RECRUITING

And 4 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Partial Epilepsy:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships